XENO TRANSPLANTS CORPORATION

As of March 31, 2008, XENO TRANSPLANTS CORPORATION carries a market capitalization of 4.44M, placing it among publicly traded companies globally. Its enterprise value stands at 4.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2008, XENO TRANSPLANTS CORPORATION has 40.36M shares outstanding.

These figures are as of March 31, 2008.

As of March 31, 2008, XENO TRANSPLANTS CORPORATION trades at an EV/EBITDA multiple of 9.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 9.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.92M versus a market cap of 4.44M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2008, XENO TRANSPLANTS CORPORATION maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2008, XENO TRANSPLANTS CORPORATION posted a negative return on equity (ROE) of -286.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -71.09, reflecting losses generated across the asset base.

As of the close on September 14, 2026, XENO TRANSPLANTS CORPORATION's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

These figures cover the twelve months ended March 31, 2008. EBITDA reached 507,869.00, while operating income came in at -507,533.00.

As of March 31, 2008, XENO TRANSPLANTS CORPORATION holds 261.00 in cash and equivalents against 480,674.00 in total debt, resulting in a net debt position of 480,413.00. Total book value stands at 33,278.00, with working capital of -945,344.00 providing operational flexibility.

XENO TRANSPLANTS CORPORATION produced -207,742.00 in operating cash flow over the twelve months ended March 31, 2008. After subtracting -307,376.00 in capital expenditures, free cash flow totaled -515,118.00 - equivalent to -0.01 per share.

These figures cover the twelve months ended March 31, 2008. Free cash flow yield is negative at -11.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.85, meaning XENO TRANSPLANTS CORPORATION raised more capital through share issuance and new debt than it returned via dividends and buybacks.

XENO TRANSPLANTS CORPORATION's most recent stock split took place on September 6, 2006 with a 2:5 split ratio.